See more : Toho Chemical Industry Company, Limited (4409.T) Income Statement Analysis – Financial Results
Complete financial analysis of Allena Pharmaceuticals, Inc. (ALNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allena Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Love Hemp Group Plc (WRHLF) Income Statement Analysis – Financial Results
- Nanhua Futures Co., Ltd. (603093.SS) Income Statement Analysis – Financial Results
- Pyxis Oncology, Inc. (PYXS) Income Statement Analysis – Financial Results
- Oisix ra daichi Inc. (3182.T) Income Statement Analysis – Financial Results
- MAGELLANIC CLOUD LIMITED (MCLOUD.BO) Income Statement Analysis – Financial Results
Allena Pharmaceuticals, Inc. (ALNA)
About Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.38M | 20.38M | 37.24M | 26.38M | 15.52M | 20.10M | 11.54M |
| General & Administrative | 11.60M | 11.60M | 9.68M | 8.64M | 5.43M | 4.08M | 2.37M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 576.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 11.60M | 11.60M | 9.68M | 9.22M | 5.43M | 4.08M | 2.37M |
| Other Expenses | 0.00 | 0.00 | 605.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 31.99M | 31.99M | 46.92M | 35.59M | 20.95M | 24.19M | 13.91M |
| Cost & Expenses | 31.99M | 31.99M | 46.92M | 35.59M | 20.95M | 24.19M | 13.91M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 510.00K | -510.00K | 270.00K | 575.00K | -443.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 363.00K | 166.00K | 163.00K | 78.00K | 73.00K | 46.00K | 98.00K |
| EBITDA | -31.97M | -32.68M | -47.18M | -35.57M | -21.58M | -24.46M | -14.15M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.34M | -31.99M | -46.92M | -35.59M | -20.95M | -24.19M | -13.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -510.00K | -859.00K | 0.00 | -55.00K | -700.00K | -321.00K | -342.00K |
| Income Before Tax | -32.85M | -32.85M | -47.34M | -35.65M | -21.65M | -24.51M | -14.25M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 510.00K | -859.00K | -419.00K | -55.00K | -700.00K | -321.00K | -342.00K |
| Net Income | -33.36M | -32.85M | -47.34M | -35.65M | -21.65M | -24.51M | -14.25M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.03 | -1.01 | -2.13 | -1.72 | -4.79 | -1.60 | -0.93 |
| EPS Diluted | -1.03 | -1.01 | -2.13 | -1.72 | -4.79 | -1.60 | -0.93 |
| Weighted Avg Shares Out | 32.51M | 32.51M | 22.18M | 20.74M | 4.52M | 15.28M | 15.29M |
| Weighted Avg Shares Out (Dil) | 32.51M | 32.51M | 22.18M | 20.74M | 4.52M | 15.28M | 15.29M |
Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
-- Reloxaliase continues to progress through ongoing pivotal Phase 3 URIROX-2 trial for enteric hyperoxaluria -- -- ALLN-346 poised to enter Phase 1 multiple-ascending dose and Phase 2a trials for hyperuricemia and gout --
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in March
NEWTON, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that...
7 Penny Stocks That Actually Have Buy Ratings
Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.
Has Allena Pharmaceuticals (ALNA) Outpaced Other Medical Stocks This Year?
Is (ALNA) Outperforming Other Medical Stocks This Year?
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in January
NEWTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that...
Steven Cohen Boots Health Care Exposure With 2 Biotech Stocks
Billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 Asset Management, established a 14.37% stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) and a 7.96% position in Allena Pharmaceuticals Inc. (NASDAQ:ALNA) on Dec. 4.
Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that,...
Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that...
Allena Pharmaceuticals Announces Appointment of David J. Clark, M.D.
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the...
Allena Pharmaceuticals Announces Initial Data from Phase 1 Trial of ALLN-346
-- Single-Ascending Doses of ALLN-346 Oral Enzyme Well-Tolerated -- -- Non- A bsorption o f ALLN-346 Demonstrated -- -- Advancing to Phase 1b Multiple - Ascending Dose Study and Phase 2 Proof-of-Concept Trial ; Initial Data from Both Studies Expected...
Source: https://incomestatements.info
Category: Stock Reports